AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02453815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-cardiac surgery
Description: all surgical procedures except cardiac
Study NCT01955707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as described in the treatment arm
Study NCT01955707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02453815 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non-cardiac surgery
Description: all surgical procedures except cardiac
Study NCT02453815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterial catheter
Description: arterial catheter
Study NCT01193257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel tablets
Study NCT01193257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study NCT01193257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablets
Study NCT01193257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orteronel Placebo
Description: Orteronel placebo-matching tablets
Study NCT03776370 — intervention group
Intervention type: PROCEDURE
Intervention: Preserve the left colonic artery
Description: Preservation of left colonic artery in rectal cancer surgery.
Study NCT03776370 — intervention group
Intervention type: PROCEDURE
Intervention: The left colonic artery is not preserved
Description: The left colonic artery was dissected in rectal cancer surgery.
Study NCT01793870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 25 mg
Description: Carvedilol 25 mg immediate release tablet
Study NCT01793870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab carvedilol 6.25 mg
Description: Carvedilol 6.25 mg immediate release tablet
Study NCT01793870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Powder carvedilol up to 2.5 mg
Description: Carvedilol up to 2.5 mg isotopically enriched drug substance powder
Study NCT01456624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megace
Description: 800mg
Study NCT01456624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-ES(B)
Description: 625mg
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
Study NCT01237951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: On Day 0, stem cells returned to body by vein over 30-60 minutes.
Study NCT01237951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
Study NCT03033329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intravenous doses of MRX-4
Description: Intravenous single escalating doses of MRX-4
Study NCT03033329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous doses of placebo
Description: Intravenous single doses of placebo to match MRX-4
Study NCT03033329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple intravenous doses of MRX-4
Description: Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
Study NCT03033329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple intravenous doses of placebo
Description: Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
Study NCT03033329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose of intravenous and oral MRX-4
Description: Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
Study NCT01817790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Nasal spray formulation (200 mcg/day)
Study NCT01817790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle for Fluticasone propionate aqueous nasal spray
Study NCT02803333 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT02789267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular dietary support
Description: Systematic and regular dietary support after radiotherapy
Study NCT03010371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
Study NCT03010371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Online Psychotherapy
Description: The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
Study NCT03010371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy (CBT) is based on the Cognitive Behavioral Stress Management (Antoni, 2003) and the training program derived from it, Breast Cancer Stress Management and Relaxation Training (B-SMART) by Antoni Michael (2003). In its Spanish version, it is a 10-session therapy aimed to reduce cancer-related emotional distress, facilitating adjustment to illness and greater quality of life. Stress management and relaxation techniques help patients to identify their own stress responses and learn alternative ways of thinking and acting in response to the demands they perceive as highly stressful.
Study NCT01802164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-absorbable composite mesh (Ethicon Physiomesh)
Description: To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
Study NCT00109590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine, enteric-coated
Description: once daily
Study NCT02125214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)
Description: Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
Study NCT00109590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: twice daily
Study NCT00109590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: single-dose at the onset of labor
Study NCT00109590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: twice daily
Study NCT04208113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School teacher training /.b
Description: The intervention is a multi-level, multi-component complex intervention. It consists of a school teacher training programme and the .b-programme to be delivered to pupils 11-15 years in the schools.~The school teacher training programme consists of three parts: 1) the establishment of own mindfulness practice by participation in the MBSR programme and sustaining mindfulness with a regular formal daily practice; 2) completion of the four days .b residential course, and 3) completion of the 3x2-days seminars on relational competences and implementation issues regarding teaching .b .~The .b programme consists of well-described, weekly 40-60 minutes classroom sessions over 10 weeks. All the sessions have a specific theme, associated teachers' notes, power points and animations. The .b programme can only be delivered with fidelity by a trained .b teacher.
Study NCT04049409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB809
Description: CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
Study NCT04049409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVB
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTX
Study NCT03006614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T
Study NCT01904981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily
Study NCT01904981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily
Study NCT02862353 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 15 ml of blood
Study NCT03254108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 2mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
Study NCT03254108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 4mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
Study NCT03254108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 8mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
Study NCT03254108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 injection 16mg
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
Study NCT03254108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan tablet 15mg
Description: Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
Study NCT03758300 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency
Description: See previous page
Study NCT03758300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: See previous page
Study NCT00894959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium Blausiegel 1
Description: Heparin sodium Blausiegel 1 5.000 UI
Study NCT00894959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodium APP
Description: Heparin sodium APP 5.000 USP
Study NCT03698344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodiesel exhaust exposure
Description: Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
Study NCT00608946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: copper
Description: intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
Study NCT00608946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01325337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation A
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Study NCT01325337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation B
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Study NCT01325337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost Formulation C
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Study NCT01325337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Study NCT01325337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil 5% solution
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Study NCT03286673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate
Study NCT03286673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricalcium Phosphate
Study NCT03286673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Study NCT02799251 — intervention group
Intervention type: OTHER
Intervention: Collection of plasma cell rate
Description: Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
Study NCT03286673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04551014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of EverLift
Description: Use of EverLift for submucosal injection prior to polypectomy
Study NCT04551014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Without use of EverLift
Description: Without use of EverLift for submucosal injection prior to polypectomy
Study NCT02221492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor GZ316455
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT02221492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT02221492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study NCT02654002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablets administered orally
Study NCT02654002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study NCT03457441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standards vision tests
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
Study NCT03457441 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OdySight medical application assessment
Description: Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
Study NCT02230969 — intervention group
Intervention type: DRUG
Intervention: peginterferon beta-1a
Description: Administered as specified in the treatment arm
Study NCT03319745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00891202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate
Description: PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Study NCT03254459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: 0.5 mg Sublingual Spray
Study NCT03254459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 4 mg Intravenous Injection
Study NCT03254459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Hydrochloride
Description: 10 mg tablet
Study NCT03254459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran
Description: 4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
Study NCT03254459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: 4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
Study NCT00979667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg twice daily for 5 days
Study NCT00979667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg twice daily for 5 days
Study NCT00979667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Oseltamivir
Description: twice daily for 5 days
Study NCT01237483 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erbitux
Description: To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
Study NCT00265356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET diagnostic imaging
Description: PET diagnostic imaging
Study NCT01737229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Biodentine™ (RD94), dentin substitute
Study NCT04518189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: lidocaine patch applied 3 hours before the procedure
Study NCT04518189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Sham patch applied 3 hours before the procedure
Study NCT00307320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Relaxation techniques training
Study NCT02923024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Ping
Description: The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.